RIODIPINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H19F2NO5
Molecular Weight	367.344
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)C1=C(C)NC(C)=C(C1C2=C(OC(F)F)C=CC=C2)C(=O)OC

InChI

InChIKey=AZVFIZVKGSPGPK-UHFFFAOYSA-N

InChI=1S/C18H19F2NO5/c1-9-13(16(22)24-3)15(14(10(2)21-9)17(23)25-4)11-7-5-6-8-12(11)26-18(19)20/h5-8,15,18,21H,1-4H3

HIDE SMILES / InChI

Molecular Formula	C18H19F2NO5
Molecular Weight	367.344
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2517404 | http://infomeds.net/foridon.html | https://www.ncbi.nlm.nih.gov/pubmed/8377339

Riodipine is the blocker of calcium channels of L-type. Riodipine is indicated for the treatment of arterial hypertension, prevention of attacks of angina pectoris. Antiepileptic effect of riodipine was manifested by a decreased frequency and amplitude of interictal discharges and a less frequent appearance of ictal discharges. Riodipine increased latency to first convulsive episodes and delayed the development of generalized tonic-clonic seizures. Detected side effects are: arterial hypotension, tachycardia, hypostasis of shins, increase of a daily urine. Allergic reactions to the drug are possible. Nitrates, tricyclic antidepressants, and other anti-hypertensive drugs are able to potentiate of riodipine effects.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Heart phosphodiesterase 2 Target ID: CHEMBL2111408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2165822	Inhibitor 8297
Voltage-gated L-type calcium channel 92 Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2992533 \| http://infomeds.net/foridon.html	Blocker 537

Conditions

Condition	Modality	Targets	Highest Phase	Product
Angina pectoris 106 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3066967 https://www.ncbi.nlm.nih.gov/pubmed/8377339 http://lekmed.ru/lekarstva/antagonisty-kalciya/foridon.html	Preventing		Approved 8429	Foridon Approved Use Indicated for the treatment of arterial hypertension the I-II foot, hypertensive crisis, prevention of attacks of stenocardia against the increased arterial pressure, prevention of attacks of an angina of exertion. Launch Date 1987
Hypertension 567 Sources: http://lekmed.ru/lekarstva/antagonisty-kalciya/foridon.html https://www.ncbi.nlm.nih.gov/pubmed/18418924 https://www.ncbi.nlm.nih.gov/pubmed/2097399	Primary		Approved 8429	Foridon Approved Use Indicated for the treatment of arterial hypertension the I-II foot, hypertensive crisis, prevention of attacks of stenocardia against the increased arterial pressure, prevention of attacks of an angina of exertion. Launch Date 1987

PubMed

Title	Date	PubMed
Effect of ryodipine on electromechanical parameters of heart and vessels, cAMP phosphodiesterase activity and swelling-contraction cycle of mitochondria.	1985	2992533

Patents

Sample Use Guides

In Vivo Use Guide

20-30 mg 3 times a day. The maximum daily dose - 150 mg. Course of treatment 2-3 weeks

Route of Administration: Oral

In Vitro Use Guide

Riodipine (10(-8) mol/l--10(-6) mol/l) suppresses contraction force and diminishes frequency of spontaneous contractions of the rabbit atria, and also displays antagonism to the effect of Ca2+ upon rabbit auricle contractions.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:04:48 GMT 2023` Edited by `admin` on `Fri Dec 15 16:04:48 GMT 2023`
Record UNII	W12VDB26LB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RIODIPINE

Official Name

English

FORIDON

Brand Name

English

RYODIPINE

Common Name

English

riodipine [INN]

Common Name

English

Riodipine [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C333